OncLive TV

David Miklos, MD, discusses anticipated sequencing challenges with the investigational CAR T-cell therapy KTE-X19 in mantle cell lymphoma.

Andrew Yee, MD, discusses the role of carfilzomib in relapsed/refractory multiple myeloma.

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses the impact of the coronavirus disease 2019 (COVID-19) on telehealth in head and neck cancer.

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.

Jean Wright, MD, discusses proton versus photon radiotherapy in breast cancer.

Thomas Powles, MD, MBBS, MRCP, director, Barts Cancer Institute, discusses the 42-month follow-up data from the phase 3 CheckMate-214 trial in advanced renal cell carcinoma (RCC).

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses combinations with venetoclax (Venclexta) in acute myeloid leukemia (AML).

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

Bob Valamehr, PhD, chief development officer at Fate Therapeutics, discusses the advantages of off-the-shelf CAR NK therapy in B-cell malignancies.

Daniel P. Petrylak, MD, professor of medicine and urology, co-leader, Cancer Signaling Networks, Yale Cancer Center, and 2017 Giant of Cancer Care® in Genitourinary Cancers, discusses the results of the phase 1b/2 EV-103 trial in bladder cancer.

Anna C. Pavlick, DO, discusses updated results from the COLUMBUS trial in metastatic melanoma.

Jonathan C. Trent, MD, PhD, discusses research efforts in bone and soft tissue sarcomas.

Hui-Zi Chen, MD, PhD, discusses the use of rapid research autopsy in metastatic ultra-hypermutated interdigitating dendritic cell sarcoma, an extremely rare cancer of dendritic origin that lacks a standardized treatment approach.

Ruth O’Regan, MD, provides insight on how the COVID-19 crisis is impacting the care of patients with breast cancer.

Alanna K. Rahm, PhD, MS, discusses alternate delivery models for genetic counseling in prostate cancer.

Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.

William K. Oh, MD, discusses adapting the phase 2 PRINT trial model to other settings in prostate cancer

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.

John A. Abraham, MD, FACS, discusses potential symptoms of tenosynovial giant cell tumor.

Robert L. Ferris, MD, PhD, discusses ongoing research with STING agonists and checkpoint inhibitors in head and neck cancer.

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Sam S. Chang, MD, MBA, discusses the importance of quality of life in prostate cancer.

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Wolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.

Richard (Rick) JaeBong Lee, MD, PhD, discusses choosing among the antidrogens available in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

Himisha Beltran, MD, discusses the limitations of tissue biopsies versus liquid biopsies in castration-resistant neuroendocrine prostate cancer.